Medicare Drug Price Negotiation Program Takes Effect: 10 Common Drugs See List Price Cuts of 38% to 79% in 2026
核心洞察
The Centers for Medicare & Medicaid Services (搜索) implemented negotiated Maximum Fair Prices for 10 widely prescribed drugs on January 1, 2026, with list price reductions ranging from 38% to 79%.
Januvia received the steepest cut, dropping from $527 to $113 per 30-day supply, while Imbruvica saw the smallest reduction at 38% off its 2023 list price.
A new $2,100 annual out-of-pocket cap for Part D covered prescriptions now limits beneficiary spending, with costs dropping to $0 once the cap is reached.
The Medicare Part D landscape shifted substantially on January 1, 2026, as the Centers for Medicare & Medicaid Services (搜索) (CMS) implemented negotiated "Maximum Fair Prices" for 10 of the program's most costly brand-name drugs under the Inflation Reduction Act's Drug Price Negotiation Program. The list price reductions range from 38% to 79% compared with 2023 prices, targeting medications that together represented roughly 20% of Medicare Part D gross drug spending.
The 10 drugs selected for this initial round span cardiovascular, metabolic, autoimmune, and oncologic indications: Eliquis and Xarelto (blood thinners); Jardiance, Januvia, and Farxiga (diabetes (搜索) medications, with Jardiance and Farxiga also indicated for heart failure (搜索) and kidney disease (搜索)); Entresto (heart failure); Enbrel (rheumatoid arthritis (搜索), psoriasis (搜索)); Stelara (psoriasis, Crohn's disease (搜索)); Imbruvica (blood cancers (搜索)); and Fiasp/NovoLog (搜索) (insulin).
Januvia received the most dramatic price reduction, with CMS cutting the 30-day list price from $527 to $113 — a 79% decrease. Imbruvica, a blood cancer therapy, saw the smallest relative reduction at 38%, though the absolute dollar impact remains substantial given its high baseline price.
How the Negotiated Prices Interact with Patient Costs
A critical distinction underlies the program's real-world impact: the negotiated discount applies to the manufacturer's list price paid by Medicare and the plan, not directly to what beneficiaries pay at the pharmacy counter. Patient out-of-pocket costs remain governed by each plan's cost-sharing structure — deductibles, copays, coinsurance tiers, and whether the beneficiary is enrolled in a Medicare Advantage plan with drug coverage or a standalone Part D plan.
For 2026, Part D includes a $2,100 annual out-of-pocket cap on covered prescription drugs. Once a beneficiary reaches that threshold through combined deductible payments, copays, and coinsurance, covered Part D medications cost $0 for the remainder of the calendar year. The cap originated at $2,000 in 2025 and indexes annually to growth in average per-capita Part D drug spending.
"For someone taking only Eliquis or Januvia, the practical effect is different," the analysis notes. "The lower negotiated price reduces the coinsurance percentage applied to a smaller number, so the monthly copay drops, but most enrollees on a single common drug never reach the $2,100 cap anyway."
For patients on high-cost therapies such as Imbruvica, Stelara, or Enbrel, the cap often exerts a larger influence on out-of-pocket spending than the negotiated price itself. A beneficiary on a $60,000-a-year specialty biologic previously faced 5% catastrophic coinsurance that could run $3,000 on the back half of the year alone. Under the 2026 structure, the entire Part D obligation tops out at $2,100.
The Medicare Prescription Payment Plan
One structural challenge persists: many high-cost drug users still incur most of their out-of-pocket liability early in the calendar year. CMS offers the Medicare Prescription Payment Plan, a free, voluntary program allowing Part D enrollees to spread out-of-pocket prescription costs across monthly installments rather than paying in full at the pharmacy counter. The $2,100 ceiling remains unchanged; the program alters only the timing of payments.
Broader Financial Context
The drug price negotiations arrive as retirees face mounting healthcare cost pressures. The 2026 Social Security cost-of-living adjustment came in at 2.8%, while healthcare services inflation ran at 3.49% year-over-year through April. A negotiated drug price that holds or reduces list prices represents one of the few line items in a Medicare budget moving in a favorable direction.
What Beneficiaries Should Do
CMS advises beneficiaries to review their Part D Explanation of Benefits to identify whether any of the 10 negotiated drugs appear on their plan. Comparing January 2026 copays to December 2025 copays for the same prescription reveals the real-world impact. For those on high-cost drugs, planning around the $2,100 cap is essential, as these patients will almost certainly reach it.
Re-shopping Part D plans during the Annual Enrollment Period (October 15 to December 7) remains critical. Plans adjust formularies and tiering annually in response to negotiated prices, and the most cost-effective plan for a given drug list in 2026 may not retain that position in 2027.
CMS has already selected the next set of drugs for negotiation, with prices taking effect in 2027 and beyond. The program is expanding, and prescriptions not on the current list may appear in subsequent rounds.